No significant predictive value of c- erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer

p53 Status and the Efficacy of Cancer Therapy in Vivo

1994 • 1,483 citations

c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer

1994 • 981 citations

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1992 • 855 citations

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.

1992 • 466 citations

Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy

1995 • 458 citations

Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6

1994 • 435 citations

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.

1996 • 423 citations

Infiltrating lobular carcinoma of the breast: Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns

1996 • 410 citations

Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines.

1993 • 309 citations

Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer.

1995 • 197 citations

Proliferation Markers in Breast Carcinoma:Mitotic Figure Count, S-Phase Fraction, Proliferating Cell Nuclear Antigen, Ki-67 and MIB-1

1995 • 180 citations

Correlation of Pretreatment Proliferative Activity of Breast Cancer With the Response to Cytotoxic Chemotherapy

1989 • 156 citations

c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer

1995 • 133 citations

Immunohistochemical detection ofHER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis

1995 • 104 citations

Expression of p53, Glutathione S -Transferase- , and Bcl-2 Proteins and Benefit From Adjuvant Radiotherapy in Breast Cancer

1997 • 99 citations

Relationship betweenp53 gene abnormalities and other tumour characteristics in breast-cancer prognosis

1996 • 97 citations

p53 Status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings.

1995 • 91 citations

C-ERBB-2 oncogens protein inIn situ and invasive lobular breast neoplasia

1991 • 85 citations

Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas

1996 • 82 citations

Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer

1997 • 81 citations

Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas.

1993 • 76 citations

p53 mutations and overexpression in locally advanced breast cancers

1994 • 74 citations

Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas

1996 • 67 citations

Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer.

1995 • 60 citations

Breast cancer proliferation measured on cytological samples: a study by flow cytometry of S-phase fractions and BrdU incorporation

1991 • 50 citations

Changes of biological features in breast cancer cells determined by primary chemotherapy

1997 • 41 citations

Ondansetron for intractable vertigo complicating acute brainstem disorders

1995 • 33 citations